FINWIRES · TerminalLIVE
FINWIRES

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

By

4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28, according to analysts polled by FactSet.

What else is happening in Research?